Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal

DOI: 10.2122/gbc - ARCHIVE

Each gbc article has now a unique Digital Object Identifier (DOI)

DOI: 2017 2013 2012 2011

2002

 
ARTICLES
ABSTRACTS
FULL TEXTS
PDF
PAGES
DOI
Introduction, Pathology...
1-3
Causation
4-6
Diagnosis, Staging...
7-10
Treatment: Early-Stage...
11-20
Accurate Prediction...
21-30
Preservation...
31-38
Optimizing Lymph...
39-42
Circulating Cancer Cells...
43-44
Effectiveness...
45-46
Impact of Surgical...
47-49
Time to Move...
50-51
Background...
52-54
Chemoprevention Studies...
55-57
Comparing Recent ...
58-63
Risks and Benefits...
64-66
Challenges in Surgical...
67-69
Does Hormonal...
70-71

 

2003

Tumor Stage-Based...
1-3
Gene-Expression...
4-6
Cyclin E...
7-9
Breast-Conserving...
10-12
Breast-Conserving...
13-17
Carcinogenesis...
18 - 21
Evidence-Based Approach...
22 - 25
Highly Effective...
26 - 29
Surgeon Volume...
30 - 32
Confirming Hypothesis...
33 - 41
Evaluating Cancer...
42 - 47


2004

Prevention...
1 - 4
Improving Decision...
5 - 12
Carcinogenesis...
13 - 22
Proof-of-Concept...
23 - 26
Endoscopic Mucosal...
27 - 35
Neoadjuvant versus...
36 - 39
New Data...
40 - 46
Standards and trends...
47 - 53
P27Kip1...
54 - 60
Gastric Cancer...
61 - 64


2005

Highlights and Consensus...
-
1 - 3
The complexity...
4 - 7
Perioperative Adjuvant...
8 - 14


2006

First randomized evidence ...
19 - 23
Antharacyclin-based chemotherapy ...
24 - 26
First report on the impact of bilateral...
15 - 18
Choosing preventive intervention...
27 - 38
Travelling in the time ...
1 - 14
Deciding on genetic testing...
55 - 57
Overexpression of Erbb2...
58 - 64
Positive Perioperative (ECF)...
49 - 54
From standard ER, HER2 to Gene Expression Profiling ...
41 - 48
Dramatic advances in cancer risk ...
39 - 40

2007

Cancer biology drives personalized management ...
1 - 11
Appropriate surgery (RO) remains the milestone ...
12 - 13
We can do better - Decisions on Primary Prevention
14 - 15
Prophylactic total gastrectomy for gastric cancer
16 - 18
Preventing CDH1 Mutation Carriers
19 - 21
Prevention of hereditary cancer syndromes
22 - 24
Risk-reducing surgery in the prevention of hereditary cancer syndromes
25 - 27
Genomewide Association Studies – Strengthens and Challenges in the Clinic ...
28 - 31
10.2122/gbc.2006.0059
The importance of surgical margin control in breast-conserving therapy...
32 - 33
10.2122/gbc.2006.0060
Reducing local recurrence after Breast-conserving surgery for breast cancer
34 - 36
10.2122/gbc.2007.0061
Increased risk of local recurrence after breast-conserving therapy in young patients
37 - 38
10.2122/gbc.2007.0062
Gene signatures and breast cancer network biology: Ready to the clinic?
39 - 40
10.2122/gbc.2007.0063
Outcomes of breast cancer patients with and without BRCA1/2 mutations
41 - 43
10.2122/gbc.2007.0064
Targeting Gastric Cancer: Inhibiting signal transduction pathways
44 - 55
10.2122/gbc.2007.0065
Current Treatment of Gastric Cancer: More Complicated than Ever
56 - 59
10.2122/gbc.2006.0066
Asssessment of Laparoscopic Approach in Gastric Cancer
59 - 61
10.2122/gbc.2006.0067
Advances in Laparoscopic Gastrectomy
62 - 65
10.2122/gbc.2007.0068
Laparoscopic Gastrectomy: Advances Enable Wide Clinical Application
66 - 69
10.2122/gbc.2007.0069
Prognosis of BRCA and non BRCA mutation carriers
70 - 72
10.2122/gbc.2007.0070
Choosing Preventive Intervention in BRCA mutation Carriers
73 - 75
10.2122/gbc.2007.0071
A Study of Tissue Bcl-2 Expression and Its Serum Levels in Breast Cancer Patients
76 - 83
10.2122/gbc.2007.0072

2008

BREAKTHROUGH
HUMAN GENOME GENETIC VARIATION AND CLINIC
1 - 8
Incorporating Genetic Testing for Guided Prevention of Contralateral Breast Cancer
9 - 12
Minimal residual disease in breast cancer: Can it be used as prognostic marker?
13 - 15
Preventing Contralateral Breast Cancer
16 - 18
Cancer origin and Metastasis - Does Local Control Affect Overall Survival for Solid Cancer?
19 - 21
Endoscopic Mucosal Resection - Is safe and Effective for Early Diffuse-type Gastric Cancer?
22 - 24
Benefits and harms in avoiding Axilla Lymphadenectomy in Breast Cancer
25 - 27
Targeting HER2 Breast Cancer With Trastuzumab, Lapatinib and Other Novel Agents: Clinical Success and Resistance
28 - 31
10.2122/gbc.2008.0080
Treatment of Localized Gastric Adenocarcinoma
74 - 79
Prognostic Value of Epidermal Growth Factor Receptor in Breast Cancer: An Indian Experience
56 - 64
10.2122/gbc.2008.0082
Tailoring surgery for breast cancer – Genetic Testing-based current practice and promises with Genomewide Association studies
45 - 52
10.2122/gbc.2008.0083
Bevacizumab for metastatic breast cancer – Promise and Concerns
53 - 55
10.2122/gbc.2008.0084
Structural genomic variation: Human Copy Number Variation Promise Towards Personalized Medicine
65 - 68
10.2122/gbc.2008.0085
Da Vinci System for Robotic Rectal Cancer Surgery
69 - 70
10.2122/gbc.2008.0086
VEGF and EGFR Antagonists for Gastric Cancer
71 - 73
10.2122/gbc.2008.0087
Personal genomics and practical personalized medicine – Overcoming challenges?
80 - 82
10.2122/gbc.2008.0088
Genetics and personal genome towards personalized breast cancer local control.
83 - 85
10.2122/gbc.2008.0089
High-volume surgeons improve esophagus cancer oncological outcomes.
86 - 88
10.2122/gbc.2008.0090
Genetic variation –SNPs/CNVs- and potential anticancer applications.
89 - 91
10.2122/gbc.2008.0091
Laparoscopic colectomy for cancer.
92 - 95
10.2122/gbc.2008.0092
Treatment of Localized Gastric Adenocarcinoma
96 - 109
10.2122/gbc.2008.0093
Epidermal Growth Factor Receptor perspectives for Breast Cancer.
110 - 112
10.2122/gbc.2008.0094
D2 vs. D4 lymphadenectomy for gastric cancer.
113 - 117
10.2122/gbc.2008.0095

2009


DNA variation-based research including GWA studies may yield in understanding “genotype-phenotype mapping” through innovative causative network brilliant models
1 - 2
H. pylori-diet and genetic factors interactions: Quantitative genetics gastric cancer targeted screening and prevention
6 - 12
Targeted Agents and Biomarkers Promises and Pitfalls: Personal Genomics, Bioinformatics and Systems Biology Drive Novel Drugs Discovery and Markers for Personalized Cancer Biomedicine.
35 - 50
Personal Genetics and impact on breast surgeon
29 - 31
Robotic Surgery: New Era in the Treatment of Solid Cancer.
13 - 18
Solid cancer is a highly complex-heterogeneous disease.
3 - 5
KRAS AND SIGNALING NETWORK: NEW THINK NEW DRUGS ERA
19 - 24
Laparoscopic Gastrectomy: Evidence for improved QOL
32 - 34
Laparoscopic Gastrectomy: HIGH-VOLUME SURGEONS
25 - 28
Bevacizumab: Limitations for Breast Cancer Treatment
29 - 30
New era in cancer surgical treatment
31 - 35
Impact of genetics and genomics in breast cancer surgery
36 - 38
Personalized Molecular cancer-targeted therapy
39 - 46
Rectal cancer resection
47 - 49
Laparoscopic Colectomy for Colon Cancer
50 - 52
Personal genomics for early Breast cancer
How targeted therapy, genetics and personal genomics may prevent local failures and improve Local outcomes.
53 - 69

2010

Systems medicine for a next-generation of biomarkers and drugs: Changing poor cancer outcomes.
1 - 23
Open or laparoscopic colorectal cancer resection: standardization and lymph nodes retried
34 - 35
Low anterior rectal resection for rectal cancer: Why laparoscopic or robotic surgery may improve outcomes?
29 - 30
Laparoscopic D2 gastrectomy: A new horizon even in the West
31 - 33
Very early (T1a,bN0) breast cancer: HER2 and algorithmic approach to predict and treat patients at high recurrence risk
36 - 44
Nipple-Sparing Mastectomy
27 - 28
Why Gastric and Breast Cancer Journal ? CDH1 and HER2
24 - 26
The new era of systems medicine and cancer networks
45 - 50
Breast cancer: Trastuzumab for HER2-positive patients and molecular systems approach
51 - 54
Challenges for personalized medicine: A 2020 vision
55 - 59
Advances in laparoscopic gastrectomy for early and advanced resectable gastric cancer
60 - 64
Endoscopic submucosal dissection for gastric tube cancer after esophagectomy
65 - 67
Challenges and expectations for novel biologics discovery in HER2-negative breast cancer
68 - 69
Genetic geographical ancestry and breast cancer: Exploring potential phenotypic clinical differences in patients from Africa and Europe
70 - 72
10.2122/gbc.2010.0125
Decision-making treatment for early breast cancer and future perspectives
73 - 82
Reversing Cancer and Ageing: Multiple Personal Genomes, Life Complexity and Myriad Clinical Challenges
83 - 87
10.2122/gbc.2010.0127
Selection and identification of DNA aptamers to gastric cancer cell SGC-7901
119-126
10.2122/gbc.2010.0128
Cetuximab, panitumumab and bevacizumab resistance in colorectal cancer: Are molecular networks the solution?
88 - 94
10.2122/gbc.2010.0129
Comparative-effectiveness research and personalized medicine: Trends and debate
95 - 101
10.2122/gbc.2010.0130
Evidence-based laparoscopic surgery for low rectal cancer
102-105
10.2122/gbc.2010.0131
Trastuzumab for small HER2-positive breast cancer? Uncertainty and new research directions
106-109
10.2122/gbc.2010.0132
Intellectual innovation and new technology in surgical oncology
110-112
10.2122/gbc.2010.0133
Western challenges with esophagectomy and follow-up
113-115
10.2122/gbc.2010.0134
Standardizing colorectal cancer treatment
116-118
10.2122/gbc.2010.0135
Next-generation management of breast and gastric cancer
127-143
10.2122/gbc.2010.0136
Sequencing Cancer Genome and investigating biomedical systems for improving surgical oncology
144-149
10.2122/gbc.2010.0137
Whole-genome sequencing and epigenome analysis revolutionize biomedical sciences
150-156
10.2122/gbc.2010.0138
Biomarkers for personalizing health: concerns, challenges and prospects
157-162
10.2122/gbc.2010.0139
KRAS-targeting agents and beyond for colorectal cancer treatment
163-169
10.2122/gbc.2010.0140
PLX4032: A novel effective anti-melanoma drug and new ways to overcome resistance
170-174
10.2122/gbc.2010.0141
Colorectal cancer targeted treatment: advances and resistance
186-192
10.2122/gbc.2010.0142
Trastuzumab: Isolated success in the adjuvant setting and a paradigm for moving toward network oncology
193-198
10.2122/gbc.2010.0143
Personalized medicine: How and when, if ever, huge challenges could be overcome?
175-185
10.2122/gbc.2010.0144
Totally robotic surgery for rectal cancer treatment: Advances and challenges
199-201

10.2122/gbc.2010.0145

2011

Cetuximab: Explaining resistance and disappointing new results
25 - 29
Eribulin, epigenome and miRNAs cancer therapeutics targets - Beyond?
1 - 18
To test my genome?
19 - 24
Breast cancer: New key phase 3 trials data on sentinel node, recurrence biopsy and bevacizumab
43 - 46
Challenges in reaching true robust novel breast cancer markers
36 - 42
Multimodal treatment including trastuzumab for gastroesophageal junction cancer: Controversy, and individualized decision.
30 - 35
MicroRNAs: A new class of therapeutic targets in cancer
53 - 58
Family history and BRCA testing: Challenges in deciding between risk-reducing surgery and surveillance including MRI
47 - 52
From Genome Sequencing to Regulatory Circuits and from Traditional to Network Medicine.
59-67
10.2122/gbc.2011.0154
Computational Biology, Quantitative Genetics and International Consortiums.
68-72
10.2122/gbc.2011.0155
Cancer prevention and prophylactic surgery: Standards and GWAS-based perspectives.
116-122
10.2122/gbc.2011.0156
Gastric cancer: Practice, Targeted Advances and novel genomics therapeutic approaches.
73 -78
10.2122/gbc.2011.0157
Sequencing Cancer Genome shapes new ways in surgical oncology.
109-115
10.2122/gbc.2011.0158
miRNAs gene expression regulation and their role in cancer prediction and therapy.
79-84
10.2122/gbc.2011.0159
New GWAS new hope for disease-risk prediction, prevention, and therapy.
85-90
10.2122/gbc.2011.0160
Aggressiveness and Complexity of Pancreatic Cancer: Research focused on tumorigenesis-based prevention or metastasis-based treatment?
91-93
10.2122/gbc.2011.0161
Cetuximab limitations and renew interest in surgical resection and research advances for improving stage IV colorectal cancer outcome.
94-96
10.2122/gbc.2011.0162
Family history and BRCA testing change surgery for breast cancer in the USA.
97-99
10.2122/gbc.2011.0163
Standard and new treatment strategy to prevent melanoma recurrence.
100-102
10.2122/gbc.2011.0164
Breast cancer biomarker: Advances, validation and novel discoveries.
113-130
10.2122/gbc.2011.0165
Genotyping vs. exome sequencing for cancer.
103-105
10.2122/gbc.2011.0166
Advances and challenges for laparoscopic rectal cancer surgery.
106-108
10.2122/gbc.2011.0167
Selecting robotic and laparoscopic surgery in surgical oncology: fast progress but need for evidence.
192-199
10.2122/gbc.2011.0168
Atlantis Mystery and Missing Heritability
139-145
10.2122/gbc.2011.0169
Network Biology-Based Medicine
131-138
10.2122/gbc.2011.0170
Avoiding axilla lymph node dissection for selected breast cancer: New sentinel lymph node dissection practice-changing trials.
187-191
10.2122/gbc.2011.0171
Improving Pancreatic Cancer Treatment with Combinatorial Chemotherapy Regimen and Erlotinib.
151-153
10.2122/gbc.2011.0172
Intracorporeal anastomosis after laparoscopic right colectomy for cancer
154-156
10.2122/gbc.2011.0173
Surgical resection and research advances for improving stage IV colorectal cancer outcome
157-158
10.2122/gbc.2011.0174
Melanoma and recurrence: Advances and challenges in the prevention and treatment strategies
159-160
10.2122/gbc.2011.0175
Laparoscopic sphincter-saving surgery for rectal cancer
161-164
10.2122/gbc.2011.0176
Single-port laparoscopic-assisted vaginal hysterectomy: Safe and effective advance
165-166
10.2122/gbc.2011.0177
Inferior mesenteric artery and colorectal cancer: Ligation vs. preservation with laparoscopic node dissection
167-169
10.2122/gbc.2011.0178
Breast Cancer: Radiotherapy at the South Egypt Cancer Institute
180-186
10.2122/gbc.2011.0179
Laparoscopic transanal sphincter preservation-rectal cancer resection
170-172
10.2122/gbc.2011.0180
Gastric cancer recurrence and laparoscopic gastrectomy
173-175
10.2122/gbc.2011.0181
Heritability and Prophylactic Surgery
176-177
10.2122/gbc.2011.0182
Laparoscopic Total Gastrectomy: Preventing Gastric Cancer in CDH1 Mutation Carriers
178-179
10.2122/gbc.2011.0183
Standard and Research for Ovarian Cancer: Emphasis on interactome-based tests for screening or treatment including HIPEC?
146-150
10.2122/gbc.2011.0184
Epigenomics-based novel anticancer therapies.
200-206
10.2122/gbc.2011.0185
Asymmetric open field-in-field can replace wedged fields in tangential whole breast irradiation
250-255
10.2122/gbc.2011.0186
Assessing resistance to neoadjuvant treatment for breast cancer
226-228
10.2122/gbc.2011.0187
Cytoreductive Surgery for Ovarian Cancer: Is Splenectomy indicated?
229-231
10.2122/gbc.2011.0188
KRAS mutation testing: Why is it now not recommended for colorectal cancer EGFR inhibitors treatment decision?
220-222
10.2122/gbc.2011.0189
Functional Genomics and Chromatin: Why understanding gene expression regulation is essential to revolutionize cancer therapy?
207-213
10.2122/gbc.2011.0190
Peritoneal recurrence: The challenge in gastric cancer treatment and efforts to prevent
232-234
10.2122/gbc.2011.0191
Total gastrectomy: Preventing hereditary diffuse gastric cancer
235-237
10.2122/gbc.2011.0192
Breast cancer risk-reducing surgery and BRCA testing
238-240
10.2122/gbc.2011.0193
Sigmoid or rectal cancer: do patients benefit from high ligation of inferior mesenteric artery?
241-243
10.2122/gbc.2011.0194
HER2 status-based selection of gastric cancer patients for trastuzumab treatment.
244-246
10.2122/gbc.2011.0195
How to prevent or treat hereditary diffuse gastric cancer?
247-249
10.2122/gbc.2011.0196
Translational advances and challenges for pharmacogenomics-based prescription of drugs
256-261
10.2122/gbc.2011.0197
Field-in-Field Technique as a Treatment of Choice in Tangential Whole Breast Irradiation
223-225
10.2122/gbc.2011.0198
Novel Techniques in Radiation Therapy
214-216
10.2122/gbc.2011.0199
Minimally invasive total mesorectal excision for extraperitoneal rectal cancer: Why patients should seek specialized hospitals and surgeons?
217-219
10.2122/gbc.2011.0200

2012

Whole-genome sequence: from research to clinical practice?
7-12
10.2122/gbc.2012.0201
Inhibiting mTOR and VEGF signaling in pancreatic neuroendocrine tumors.
13-19
10.2122/gbc.2012.0202
New standard targeted therapy for pancreatic neuroendocrine tumors
44-49
The up and down of KRAS testing for personalized colorectal cancer treatment
29-31
10.2122/gbc.2012.0204
From whole-genome sequencing to gene expression regulation: Perspectives for improving oncological outcomes.
1-6
10.2122/gbc.2012.0205
Gastric cancer recurrence: Is it influenced by laparoscopic gastrectomy?
20-22
10.2122/gbc.2012.0206
Monitoring EGFR plasma levels: Is it a biomarker for colorectal cancer?
32-34
10.2122/gbc.2012.0207
Pancreatic adenocarcinoma: a grand challenge
35-37
10.2122/gbc.2012.0208
Laparoscopic Sentinel Node Biopsy in Solid Cancer
23-25
10.2122/gbc.2012.0209
From Asia to Europe: Laparoscopic and robotic gastrectomy for cancer
26-28
10.2122/gbc.2012.0210
Laparoscopic Right colectomy
38-40
10.2122/gbc.2012.0211
Economic crisis and laparoscopic surgery
41-43
Solid cancer: Evaluating potential efficacy of epigenetic drugs.
102-107
10.2122/gbc.2012.0213
Progress in treating laparoscopically advanced gastric cancer
79-81
10.2122/gbc.2012.0214
Precision medicine: Neoadjuvant treatment and laparoscopic rectal cancer resection
82-84
10.2122/gbc.2012.0215
Management of advanced non-clear cell renal carcinoma.
94-101
10.2122/gbc.2012.0216
Laparoscopic gastrectomy: Challenges and perspectives in predicting morbidity and relapse risk in gastric cancer.
85-87
10.2122/gbc.2012.0217
Safety and quality of life improvement expand laparoscopic resection for gastric cancer
88-90
10.2122/gbc.2012.0218
Pre-treatment diagnostics of esophageal cancer and the role of EUS
91-93
10.2122/gbc.2012.0219
Science and technology: revealing genome networks for improving health
58-64
10.2122/gbc.2012.0220
Tumor heterogeneity-based personalized oncology
72-78
10.2122/gbc.2012.0221
Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome?
53-57
10.2122/gbc.2012.0222
Transcriptome mapping: ER-binding sites dynamics reveal new strategy for breast cancer biomarkers
50-52
10.2122/gbc.2012.0223
‘Sequence everything' strategy in the clinical cancer genome era
65-71
10.2122/gbc.2012.0224
Predictive molecular tools to personalized gastric cancer  targeted therapy.
166-179
10.2122/gbc.2012.0225
Robots and surgeons: Do patients benefit?
140-142
10.2122/gbc.2012.0226
The emerging role of miRNAs in translational cancer medicine.
180-195
10.2122/gbc.2012.0227
Cancer single pathways inhibitors: More resistance than durable success in the clinic
111-117
10.2122/gbc.2012.0228
Tumor diversity: Implementing NGS into clinic
121-126
10.2122/gbc.2012.0229
Neoadjuvant treatment and laparoscopic rectal cancer: Precision genomic medicine essential for improving patient's outcomes.
143-145
10.2122/gbc.2012.0230
Gastric cancer perspectives: Laparoscopic surgery and systems approach polypharmacology.
146-148
10.2122/gbc.2012.0231
Breast cancer advances in clinical cancer genome era: from conventional to integrative genome analysis.
149-150
10.2122/gbc.2012.0232
100 breast cancer genome sequencing: Heterogeneity-based diagnostic and therapeutic perspectives.
127-130
10.2122/gbc.2012.0233
Overcoming resistance to cetuximab or panitumumab in KRAS wild-type colorectal cancer.
131-134
10.2122/gbc.2012.0234
Resistance to everolimus treatment of renal cancer, intratumor heterogeneity and new therapeutic approaches.
118-120
10.2122/gbc.2012.0235
Novel breast cancer subtypes with integrative genomic and transcriptome analysis.
108-110
10.2122/gbc.2012.0236
Vemurafenib plus cetuximab or gefitinib for BRAF(V600E) mutant colorectal cancer.
151-153
10.2122/gbc.2012.0237
Preoperative chemoradiotherapy for rectal cancer: Why revision and concerns are now shaped?
154-156
10.2122/gbc.2012.0238
Total mesorectal excision for rectal cancer: Laparoscopic or robotic approach?
157-159
10.2122/gbc.2012.0239
Dual inhibition of HER2 for a safe increase of efficacy in breast cancer.
160-162
10.2122/gbc.2012.0240
Everolimus added to aromatase inhibitors for improving hormone-receptor-positive breast cancer outcomes.
163-165
10.2122/gbc.2012.0241
Triple-negative breast cancer: From microarrays basal-like subtype to NGS molecular classification and new drugs development.
135-139
10.2122/gbc.2012.0242
Tyrosine kinase inhibitors expand indications for surgical resection of advanced GIST.
233-235
10.2122/gbc.2012.0243
Healthy longevity: Approaching life mystery in genome science era.
226-232
10.2122/gbc.2012.0244
Cellular signaling networks exploration for clinical applications.
221-225
10.2122/gbc.2012.0245
Personalized medicine through genome science and network biology advances.
216-220
10.2122/gbc.2012.0246
Adding Fulvestrant to Anastrozole prolongs survival in Breast Cancer.
211-215
10.2122/gbc.2012.0247
Innovative drug targets: Cooperative DNA, RNA and proteins networks.
196-202
10.2122/gbc.2012.0248
Improving survival with trastuzumab emtansine for HER2-positive breast cancer.
203-207
10.2122/gbc.2012.0249
Cancer Biomarkers: Pitfalls with traditional research and novel integrated genome analysis opportunities.
236-238
10.2122/gbc.2012.0250
Trametinib plus dabrafenib : Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma.
208-210
10.2122/gbc.2012.0251
Advances and limitations with multimodal treatment of Colorectal cancer liver metastases.
239-241
10.2122/gbc.2012.0252

2013
Advances in gastric cancer: laparoscopic total gastrectomy, trastuzumab-emtansine and integrated genomic analysis.
-
Statins for reducing cancer death risk? Molecular evidence vs. statistics.
-

2017

Precision in targeting breast cancer genome.
1-6
Therapeutic intervention of Hepatic, Billiary and Pancreatic cancer genomes in time and space.
13-19
Discovering novel genes and druggable mutations in gastric cancer by applying Next-Generation Sequencing.
20-30
Potential clinical implications of Next-Generation Sequencing in Liver, Billiary, and Pancreatic cancer
31-66
Palbociclib a novel drug for Breast Cancer patients.
7-12

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.



Search only trustworthy HONcode health websites:

last update: 25 February 2017